Bioqual, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended February 28, 2022
April 21, 2022 at 02:33 pm EDT
Share
Bioqual, Inc. reported earnings results for the third quarter and nine months ended February 28, 2022. For the third quarter, the company reported sales was USD 17.13 million compared to USD 12.58 million a year ago. Net income was USD 0.856588 million compared to USD 0.97596 million a year ago. Basic earnings per share from continuing operations was USD 0.96 compared to USD 1.09 a year ago. Diluted earnings per share from continuing operations was USD 0.96 compared to USD 1.09 a year ago.
For the nine months, sales was USD 47.81 million compared to USD 41.07 million a year ago. Net income was USD 3.37 million compared to USD 4.2 million a year ago. Basic earnings per share from continuing operations was USD 3.77 compared to USD 4.7 a year ago. Diluted earnings per share from continuing operations was USD 3.77 compared to USD 4.7 a year ago.
Bioqual, Inc. is engaged in performing contract research services, which is focused on in vivo models of human diseases, including COVID-19, acquired immune deficiency syndrome (AIDS), influenza, Mpox, respiratory syncytial virus (RSV) infection, Flavivirus infections, including zika and dengue, malaria, hepatitis, and cancer. It is involved in the evaluation of vaccines, vaccine therapeutics, microbicides, and drug therapies. The Company also performs in vitro contract research services. The in vitro services include sample processing, virus stock generation, quantitation of infectious virus, virus neutralization assays, hemagglutination inhibition assay, quantitative PCR, antigen and antibody ELISA detection assays, flow cytometry, lymphocyte proliferation and other cell-based assays. It also provides research services in herpes simplex in rodents, filariasis in rhesus macaques, chikungunya in rodents and macaques and dengue in rodents and macaques.
BIOQUAL, INC. 
